PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1494844
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1494844
According to Stratistics MRC, the Global Cryo-Electron Microscopy Market is accounted for $1.42 billion in 2024 and is expected to reach $3.05 billion by 2030 growing at a CAGR of 13.60% during the forecast period. Due to its ability to enable researchers to see bio molecular structures in unprecedented detail, cryo-electron microscopy, or cryo-EM, has completely changed the field of structural biology. Using an electron microscope at extremely low temperatures, samples are imaged using this technique, which involves rapidly freezing them to preserve their natural state. High-resolution images of biological macromolecules in their natural habitat can be obtained using cryo-EM without the need for chemical fixation or staining. Moreover, significant advancements in the domains of biochemistry, pharmacology, and virology have resulted from its capacity to capture dynamic molecular structures.
According to the World Health Organization (WHO), access to essential medicines is a fundamental human right, and ensuring equitable distribution and affordability of these medicines is critical for achieving global health goals.
Growing need for drug development and discovery
Cryo-EM has become a potent tool in the pharmaceutical industry for lead optimization, structural elucidation of drug targets, and rational drug design. The capacity to observe dynamic protein-drug interactions and macromolecular complexes at near-atomic resolution provides significant insight into the potential therapeutics' mechanisms of action. Additionally, Cryo-EM services and expertise are in high demand as drug discovery pipelines shift to focus more on biologics, membrane proteins, and difficult drug targets, which is driving market expansion.
Complexity of data analysis and sample preparation
The preparation of grids, vitrification, and imaging conditions for cryo-EM samples necessitates specific knowledge and tools. A major barrier to entry for inexperienced users is the laborious and complicated workflows involved in sample preparation, in addition to the requirement for proficiency in data analysis and cryo-EM techniques. Furthermore, cryo-EM experiments produce massive amounts of raw data, which calls for sophisticated image processing algorithms and a reliable computing infrastructure for data analysis and structural refinement.
Technological progress in hardware and software
There are many chances for businesses to be creative and provide cutting-edge cryo-EM hardware and software. This involves developing and producing next-generation electron microscopes with enhanced automation, sensitivity, and resolution. Moreover, there is a growing need for user-friendly software platforms for image processing, data acquisition, and structural analysis. This presents opportunities for software developers to create tools that are efficient and easy to use, which can improve the user experience and streamline the cryo-EM workflow.
Market saturation and competitive pressures
There are a growing number of manufacturers, service providers, and research institutions offering cryo-EM solutions, which is congesting the cryo-EM market. Price wars, shrinking profit margins, and the commoditization of cryo-EM goods and services are possible outcomes of fierce competition. Additionally, the industry may experience slower revenue growth, lower profitability, and more industry consolidation as a result of market saturation, as smaller firms find it more difficult to compete with more established, larger firms.
The cryo-electron microscopy (cryo-EM) market has been impacted by the COVID-19 pandemic in a number of ways. The pandemic increased demand for cryo-EM in researching the virus's structure, host interactions, and drug development, even though it initially disrupted supply chains, manufacturing operations, and research activities, causing delays in instrument installations, service contracts, and cooperative projects. Cryo-EM has become widely used in COVID-19 research due to the pressing need to comprehend the molecular mechanisms of SARS-CoV-2 and expedite the development of vaccines, therapeutics, and diagnostics. Moreover, the adoption of cloud-based cryo-EM data analysis platforms and remote access solutions has been accelerated by the shift towards remote work and virtual collaboration.
The Lipid Nanoparticle Formulations (LNFS) segment is expected to be the largest during the forecast period
Due to their extensive application in the delivery of genetic materials like mRNA for vaccines and therapeutics, Lipid Nanoparticle Formulations (LNFs) command the largest market share in cryo-electron microscopy (Cryo-EM). These lipid nanoparticles can be imaged at high resolution using cryo-electron microscopy (Cryo-EM), providing information about their size, composition, and structural honesty. Additionally, advanced pharmaceutical development requires the use of liposome-forming factors (LNFs) due to their biocompatibility and capacity to encapsulate and safeguard delicate payloads.
The Transmission Electron Microscopy (TEM) segment is expected to have the highest CAGR during the forecast period
The transmission electron microscopy (TEM) segment is expected to have the highest CAGR in the cryo-electron microscopy (Cryo-EM) market. The need for high-resolution imaging and structural analysis of biological macromolecules is growing, and this growth is being driven by the need to advance materials science, structural biology, and drug discovery. Furthermore, researchers attempting to comprehend intricate biological processes and molecular structures find that TEM is invaluable due to its capacity to produce detailed images at the atomic level in their native state, especially when used in conjunction with cryo-TEM.
The market for cryo-electron microscopy, or cryo-EM, is dominated by North America due in large part to the region's concentration of major industry players, solid infrastructure for research, and large investments in cutting-edge technology. The region's emphasis on science and technology, along with strong funding initiatives from both public and private entities, drives advancements in the use of cryo-EM in a variety of fields, such as materials science, pharmaceuticals, and structural biology. Moreover, the concentration of top academic institutions and biopharmaceutical firms encourages cooperation and creativity, which strengthens North America's position as the market leader for cryo-EM products.
The cryo-electron microscopy (Cryo-EM) market is growing at the highest CAGR in the Asia-Pacific region due to rapid industrialization, rising R&D spending, and a growing uptake of cutting-edge technologies in a variety of industries. The demand for cryo-EM solutions is driven by the region's growing biotechnology and pharmaceutical industries as well as growing government initiatives to support scientific research and innovation. Additionally, cryo-EM market growth in the Asia-Pacific region is further accelerated by the presence of a large pool of highly skilled researchers and scientists, as well as partnerships with international organizations and academia.
Key players in the market
Some of the key players in Cryo-Electron Microscopy market include Charles River Laboratories, Hitachi High-Technologies Corporation, Intertek Group Plc, Caliber Imaging & Diagnostics, Lasertec Corporation, HORIBA, Ltd, Olympus Corporation, Gatan, Inc., JEOL Ltd, Oxford Instruments, Nikon Instruments Inc, Keyence Corporation, Helmut Hund Gmbh, Danaher, Creative Biostructure, ZEISS International and Thermo Fisher Scientific.
In May 2024, Intertek announced an agreement to acquire Base Metallurgical Laboratories and Base Met Labs US on Monday, which provides metallurgical testing services within the minerals sector in North America, for an undisclosed sum. The AIM-traded firm said the acquisition came ahead of expected heightened demand for diverse energy sources and minerals to sustain a growing global population.
In May 2024, Hitachi High-Tech and Roche have extended their partnership, committing to at least 10 years of additional collaboration. Bringing together the companies' expertise and track record in diagnostics innovation, engineering and manufacturing, the renewed contract further strengthens the two companies' long lasting partnership.
In February 2024, Charles River Laboratories International, Inc. announced a strategic agreement with Wheeler Bio, Inc., an antibody contract development and manufacturing organization (CDMO) focused on preclinical and early clinical supply of recombinant proteins, providing clients access to Wheeler's Portable CMC platform.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.